Non-interventional, Prospective, Multicenter Study to Assess Efficacy and Safety of MabtheRA (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response or Intolerance to One Anti-TNF Agent - FAST 2 SWITCH Program
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms FAST-2-SWITCH
- Sponsors Roche
- 23 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
- 20 Oct 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov